This question is testing the candidate’s knowledge of the side effects of different antiretroviral agents used in the treatment of HIV. In this case, the patient developed poor sleep, nightmares, low mood, and suicidal ideation shortly after starting HAART, indicating a possible psychiatric side effect of one of the medications.

The correct answer is Efavirenz, which is a non-nucleoside reverse transcriptase inhibitor known to cause neuropsychiatric side effects, such as insomnia, vivid dreams, depression, and suicidal ideation. It is important for healthcare providers to be aware of these potential side effects and monitor patients closely, especially those without a history of mental health issues.

The other options provided in the question (Emtricitabine, Lamivudine, Rilpivirine, and Tenofovir) are also commonly used antiretroviral agents but are not typically associated with the psychiatric side effects described in the case. Emtricitabine and Lamivudine are nucleoside reverse transcriptase inhibitors, Rilpivirine is a non-nucleoside reverse transcriptase inhibitor, and Tenofovir is a nucleotide reverse transcriptase inhibitor. Each of these medications has its own set of potential side effects, but in this case, the symptoms described are most likely due to Efavirenz.

Cotrimoxazole is an antibiotic commonly used to prevent and treat infections in infants who are exposed to HIV. In the context of HIV-exposed infants, it is important to continue cotrimoxazole until it is deemed safe to stop based on certain criteria.

Cotrimoxazole should be stopped for infants when PCR (Polymerase Chain Reaction) testing is negative for HIV ≥ 6 weeks after full cessation of breastfeeding AND the infant is clinically HIV negative. This criteria ensures that the infant has not been infected with HIV and is no longer at risk of developing HIV-related infections.

Therefore, stopping cotrimoxazole in this scenario is safe and appropriate as it indicates that the infant is no longer in need of the antibiotic for HIV prevention.

The question is asking which of the listed options is NOT considered an antenatal risk factor for referral to a community health worker (CHW).

Teenage pregnancy, low birth weight baby, any maternal problem during or post-delivery, and substance use (tobacco, drugs, alcohol) are all commonly recognized antenatal risk factors that may warrant referral to a CHW for additional support and care.

Having a previous history of depression or anxiety is not specifically mentioned as an antenatal risk factor for referral to a CHW in the text. While mental health issues can certainly impact pregnancy and should be addressed, they may not always be included in the initial list of risk factors for referral to a CHW.

Therefore, the correct answer is: Having a previous history of depression or anxiety.

When initiating antiretroviral therapy (ART) for clients with HIV who weigh 20 kg or more, it is important to consider factors such as tolerability, drug interactions, and resistance. Dolutegravir (DTG) is preferred in this population for several reasons.

Firstly, DTG has been shown to have improved tolerability compared to other ART medications. This means that clients are less likely to experience side effects that may impact their adherence to treatment. Additionally, DTG has few drug interactions, making it easier to incorporate into a client’s existing medication regimen without causing complications.

Furthermore, DTG has a high barrier to resistance, meaning that it is less likely for the HIV virus to develop resistance to this medication compared to others. This is important for long-term treatment success and preventing treatment failure.

Hepatitis A is a type of viral infection that affects the liver. Unlike hepatitis B and C, hepatitis A does not typically lead to chronic infection. In fact, chronic hepatitis and carrier state do not occur in hepatitis A infection.

When a person is infected with hepatitis A, their immune system is able to clear the virus from their body within a few weeks to months. Once the infection has been resolved, the person develops complete immunity to the virus, meaning they cannot be reinfected with hepatitis A in the future.

Therefore, the correct answer is: None – Chronic hepatitis and carrier state does not occur in hepatitis A infection and complete immunity is attained after infection.

Live virus vaccines contain a weakened or attenuated form of the virus, which can still replicate in the body but typically does not cause disease. Examples of live virus vaccines include Vaccinia (smallpox), Measles, Mumps, Rubella (MMR combined vaccine), Varicella (chickenpox), Influenza (nasal spray), Rotavirus, Zoster (shingles), and Yellow fever.

On the other hand, inactivated vaccines contain killed or inactivated forms of the virus or bacteria, which cannot replicate in the body. Examples of inactivated vaccines include Polio (IPV), Hepatitis A, and Rabies.

Based on this information, the vaccines that do not contain live organisms are Polio (Salk), Typhoid (TY 21a), and Polio (Salk) (listed twice in the question). These vaccines are inactivated vaccines, meaning they do not contain live organisms.

The question is asking which of the listed diseases have antibodies available for treatment. The diseases listed are Hepatitis A, Hepatitis B, Measles, and Rabies.

– Hepatitis A: There is no specific treatment for hepatitis A, but the hepatitis A vaccine is effective for prevention.
– Hepatitis B: Antiviral treatment may be required in some cases, but there are no drugs available that can clear the infection. However, treatment can stop the virus from replicating.
– Measles: There is no specific treatment for measles, but most people will recover with rest and supportive care. Prevention is key, and children are vaccinated against measles.
– Rabies: Treatment after rabies exposure can prevent the disease if administered promptly. This includes human rabies immunoglobulin and rabies vaccine.

Therefore, the correct answer is Rabies, as there are antibodies available for treatment of the condition.

Atazanavir is a protease inhibitor commonly used in the treatment of HIV. One of the known side effects of atazanavir is jaundice, which can cause yellowing of the skin and sclerae. This side effect is typically seen within the first few weeks of starting the medication. In this case, the timing of the symptoms aligns with the initiation of atazanavir therapy, making it the most likely culprit.

Oral Candidiasis and its Association with Immune System Defects

Oral candidiasis, a fungal infection in the mouth, is a concerning condition in young healthy individuals as it may indicate an underlying defect in the immune system. Further investigation is necessary to identify the root cause of the infection. In London, men who have sex with men have a high prevalence of HIV, which is a likely diagnosis in such cases. HIV weakens the immune system, making individuals more susceptible to infections and other health complications.

Apart from HIV, other immune system defects may also lead to oral candidiasis. Recurrent attacks of shingles in a young person may also indicate a weakened immune system. Additionally, HIV infection is a predisposing factor for deep vein thrombosis (DVT), a condition where blood clots form in the veins deep within the body. Therefore, it is crucial to investigate the underlying cause of oral candidiasis and other related conditions to ensure timely diagnosis and appropriate treatment.

Overall, oral candidiasis is a red flag for immune system defects, and healthcare professionals should be vigilant in identifying and addressing the root cause of the infection.

Congenital Cytomegalovirus (CMV) infection is a common viral infection that can be passed from mother to baby during pregnancy. It is estimated that CMV affects about 1 in 150 pregnancies. Of those pregnancies affected by CMV, about 30% will transmit the virus to the fetus. And of those fetuses that are infected with CMV, about 30% will show symptoms of the infection.

Therefore, out of 200 pregnancies, 1 will be affected by CMV. Out of those affected pregnancies, 30% will transmit the virus to the fetus, resulting in about 0.3 fetuses being infected. And out of those infected fetuses, about 30% will show symptoms of the infection, resulting in about 0.09 fetuses being affected.

So, the overall likelihood of a fetus being affected by congenital CMV infection is about 1 in 1500 pregnancies.

Bacteriostatic antibiotics work by inhibiting the growth or reproduction of bacteria, while bactericidal antibiotics work by directly killing bacteria. In this case, Penicillin is a bactericidal antibiotic because it inhibits cell wall synthesis, leading to bacterial cell death. Tetracycline, Erythromycin, and Sulphonamides are bacteriostatic antibiotics because they slow down bacterial growth or reproduction. Chloramphenicol is also primarily bacteriostatic, although it can exhibit bactericidal action in high concentrations. Therefore, the correct answer to the question is Penicillin.

Any blood test used to detect HIV infection must have a high degree of sensitivity (the probability that the test will be positive if the patient is infected) and specificity (the probability that the test will be negative if the patient is uninfected). Unfortunately, no antibody test is ever 100 % sensitive and specific. Therefore, if available, all positive test results should be confirmed by retesting, preferably by a different test method. HIV antibody tests usually become positive within 3 months of the individual being infected with the virus (the window period). In some individuals, the test may not be positive until 6 months or longer (considered unusual). In some countries, home testing kits are available. These tests are not very reliable, and support such as pre and post test counselling is not available.

Chickenpox is a common childhood illness caused by the varicella-zoster virus. One of the hallmark symptoms of chickenpox is the development of a maculopapular rash, which consists of both flat and raised lesions on the skin. This rash typically starts on the back or chest and then spreads to other parts of the body. In addition to the rash, individuals with chickenpox may also experience fever, fatigue, and itching.

Given the presentation of a fever and maculopapular rash on the back in a 12-year-old child, the most likely diagnosis would be chickenpox. Other conditions such as measles, rubella, Kawasaki disease, and scarlet fever may also present with fever and rash, but the specific characteristics of the rash in this case point towards chickenpox as the most likely cause. It is important for the child to be evaluated by a healthcare provider for a proper diagnosis and appropriate treatment.

When a client on TLD (tenofovir/lamivudine/dolutegravir) for at least 2 years has a persistent non-suppressed viral load, it is important for clinicians to address this issue promptly. The first step should be to provide enhanced adherence counseling (EAC) to ensure the client is taking their medication as prescribed. If adherence is confirmed to be above 80%, resistance testing may be considered to determine if there is any drug resistance that is contributing to the lack of viral suppression.

Switching to a non-DTG-containing regimen without further tests is not recommended as it may not address the underlying issue causing the non-suppressed viral load. Discontinuing ART treatment entirely is also not recommended as it can lead to a resurgence of the virus and potential harm to the client’s health. Increasing the dosage of TLD or switching to a regimen containing only NRTIs may not be effective in achieving viral suppression if there is underlying drug resistance.

Therefore, the best course of action is to provide EAC and consider resistance testing if adherence is confirmed to be above 80%. This approach allows clinicians to address potential adherence issues and identify any drug resistance that may be contributing to the non-suppressed viral load, leading to more effective management of the client’s HIV treatment.

Hepatitis B is a viral infection that affects the liver and can lead to both acute and chronic disease. Chronic hepatitis B infection is indicated by the persistence of HBsAg (hepatitis B surface antigen) for more than 6 months. This means that the virus is still present in the body and the person is at risk for long-term liver damage.

Hepatitis B vaccination is now part of routine childhood immunization schedules, given at 2, 3, and 4 months of age. It is also given to babies born to hepatitis B infected mothers at birth, four weeks, and 12 months old. This vaccination helps protect against the virus and prevent the development of hepatitis B infection.

There is no specific treatment for acute hepatitis B infection, as it is usually self-limiting and resolves on its own. However, antiviral medications may be considered for those with chronic hepatitis B infection, as they can help reduce the risk of liver damage and liver cancer in the long term.

Overall, it is important to get vaccinated against hepatitis B, especially for children and individuals at risk of exposure to the virus, and to seek medical advice for appropriate management of the infection.

Investigating Pruritus in a Male Patient

Pruritus, or itching, can be a symptom of various underlying conditions. In the case of a male patient without apparent cause of pruritus, an HIV antibody test would be the most appropriate first-line investigation, along with other tests such as blood sugar, thyroid profile, and urea and electrolytes. This is because HIV infection can present with intractable pruritus before other symptoms appear. Allergen skin tests may be used in suspected allergic reactions, but they would be inappropriate in this case as there is no indication of such a reaction. The anti-M2 antibody test is used for primary biliary cirrhosis, which is a rare possibility in this case. A chest x-ray is not a useful first-line test as there is no indication of malignancy. Kidney diseases can give rise to pruritus, but there is no mention of kidney disease here. It is important to consider the patient’s medical history, including any potential risk factors such as IV drug abuse, which may be the source of infection. Further investigations may be necessary depending on the results of initial tests.

Chronic active hepatitis due to hepatitis B virus carries an increased risk of subsequent hepatocellular carcinoma. This is because chronic inflammation and liver damage caused by the virus can lead to the development of liver cancer over time. Marked elevation of serum transaminase levels is also commonly seen in chronic active hepatitis B.

Chronic active hepatitis B is actually more common in men than in women. It is not typically associated with positive hepatitis D serology, as hepatitis D is a separate virus that requires hepatitis B for replication.

Corticosteroids are not typically used to treat chronic active hepatitis B, as antiviral medications are the mainstay of treatment. Therefore, it does not respond well to corticosteroids.

Overall, the most important point to remember is the increased risk of hepatocellular carcinoma in patients with chronic active hepatitis B.

Clients diagnosed with DS-TB at a non-neurological site with a CD4 count of less than 50 cells/μL are considered to have advanced HIV disease. In these cases, it is recommended to initiate ART within 2 weeks of starting TB treatment to reduce the risk of mortality and improve outcomes.

Initiating ART early in these patients can help to improve immune function, reduce the risk of opportunistic infections, and decrease the likelihood of TB treatment failure. Delaying ART in these individuals can lead to increased morbidity and mortality due to the high risk of disease progression and complications associated with advanced HIV disease.

Therefore, the correct action to take for clients diagnosed with DS-TB at a non-neurological site with CD4 < 50 cells/μL is to initiate ART within 2 weeks of starting TB treatment. This approach is in line with current guidelines and best practices for the management of HIV/TB co-infection in individuals with advanced HIV disease.

In infants under 3 months of age, a fever of 38 degrees or higher is considered to be a significant concern as their immune systems are not fully developed and they are at a higher risk for serious infections. Therefore, the most appropriate course of action in this scenario would be to admit the baby for infection screening and start IV antibiotics. This is because infants at this age are more vulnerable to infections such as sepsis, meningitis, or urinary tract infections, which can progress rapidly and have serious consequences if not treated promptly.

Giving an antipyretic and asking the parents to come back later may temporarily reduce the fever, but it does not address the underlying cause of the fever. Similarly, observing the baby for 24 hours or reassuring the parents without conducting further tests could delay necessary treatment and potentially worsen the baby’s condition.

Overall, admitting the baby for infection screening and starting IV antibiotics is the most appropriate course of action to ensure prompt and effective treatment for any potential serious infections.

Dolutegravir (DTG) is the ART drug associated with an increased risk of neural tube defects (NTDs) if used during the periconception period. Neural tube defects are birth defects that affect the brain, spine, or spinal cord of a developing fetus. Studies have shown that women who were taking DTG at the time of conception or early pregnancy had a higher risk of having a child with NTDs compared to women taking other ART drugs.

This increased risk has led to recommendations for careful counseling and consideration of alternative regimens for women of childbearing potential who are taking DTG. It is important for healthcare providers to discuss the potential risks and benefits of DTG with their patients and to consider switching to a different ART drug if pregnancy is planned or possible. This can help to minimize the risk of NTDs and ensure the health and safety of both the mother and the developing fetus.

Clostridium infection is best described as being caused by anaerobic Gram-positive bacilli. Clostridium bacteria are anaerobes, meaning they thrive in environments without oxygen. They are also Gram-positive, which means they have a thick cell wall that retains a violet dye during the Gram staining process. Clostridium bacteria are typically rod-shaped and are capable of forming endospores, which are resistant structures that allow them to survive in harsh conditions. Some important human pathogens within the Clostridium genus include Clostridium botulinum, which causes botulism, and Clostridium difficile, a common cause of diarrhea.

Assessing renal function before initiating TDF-containing regimens is important because TDF is primarily excreted through the kidneys. If a patient already has impaired renal function, TDF may accumulate in the body and lead to potential toxicity. By assessing renal function before starting TDF, healthcare providers can determine if the patient’s kidneys are functioning well enough to safely metabolize and excrete the drug.

The primary reason for assessing renal function before initiating TDF-containing regimens is to ensure safe use of the drug without exacerbating pre-existing renal impairment. This is important for preventing potential complications and adverse effects that may arise from TDF accumulation in the body. Monitoring renal function allows healthcare providers to adjust the dosage or consider alternative treatment options if necessary to minimize the risk of kidney-related complications.

The ideal time frame for initiating ART in all clients without contraindications is within 7 days, with the same day initiation if possible. This recommendation is based on the 2023 ART Clinical Guidelines which emphasize the importance of early initiation of ART in people living with HIV (PLHIV).

Initiating ART within 7 days of diagnosis and on the same day if possible has been shown to be crucial in controlling the virus, reducing viral load, and preventing disease progression. Early initiation of ART also helps in reducing the risk of transmission of HIV to others.

Therefore, it is important for healthcare providers to prioritize early initiation of ART in all clients without contraindications to ensure optimal health outcomes for PLHIV.

For term neonates from birth to less than 4 weeks of age and weighing ≥ 3.0 kg, the ART regimen consists of Zidovudine (AZT) 4 mg/kg/dose twice daily, Lamivudine (3TC) 2 mg/kg/dose twice daily, and Nevirapine (NVP) administered as 6 mg/kg/dose twice daily. These specific dosages are tailored to the neonate’s weight and age to effectively manage HIV.

Tenofovir (TDF) is an antiretroviral medication commonly used to treat HIV and hepatitis B. One of the main side effects associated with Tenofovir is kidney injury. This can manifest as decreased kidney function, proteinuria, and even acute kidney failure in severe cases. It is important for healthcare providers to monitor kidney function regularly in patients taking Tenofovir to detect any signs of kidney injury early on.

Other side effects of Tenofovir include bone loss, which can lead to osteoporosis or fractures, and Fanconi syndrome, a rare disorder that affects the kidneys’ ability to reabsorb certain substances. It is important for patients to be aware of these potential side effects and to report any symptoms to their healthcare provider promptly.

In conclusion, while Tenofovir is an effective medication for treating HIV and hepatitis B, it is important to be aware of the potential side effects, particularly kidney injury, and to monitor for any signs of these side effects during treatment.

In this case, the 32-year-old lady is found to be hepatitis B surface antigen positive for more than six months, with negative HBeAg, negative HBV DNA, and normal liver function tests. This indicates that she has chronic hepatitis B infection. The best option for further management would be to not initiate antiviral therapy but to monitor her serology regularly. This is because her liver function tests are normal, and there is no evidence of active viral replication. Antiviral therapy is typically recommended for patients with evidence of active viral replication or liver inflammation. Additionally, there is no indication for a liver biopsy in this case as her liver function tests are normal and there are no signs of advanced liver disease. Monitoring her serology over time will help determine if there are any changes in her infection status that may warrant treatment in the future.

Measles is a highly contagious viral infection that can lead to severe illness and complications, especially in young infants. In this scenario, the 8-month-old baby boy has come into close contact with another child with measles, putting him at risk for contracting the infection.

The most appropriate management in this situation would be to administer the MMR vaccine now, as well as measles immunoglobulin. This is because the baby is younger than 12 months and therefore at higher risk for severe illness from measles. The MMR vaccine can be given in place of immunoglobulin if administered within 72 hours of exposure, which is why it is recommended to give both the vaccine and immunoglobulin now.

It is important to protect young infants from measles, as they are more vulnerable to complications from the infection. By providing both the MMR vaccine and measles immunoglobulin, the baby can receive immediate protection against measles and reduce the risk of developing the infection.

Persistent watery diarrhea in a patient with HIV is most likely caused by Cryptosporidium. Cryptosporidium is a parasite that can cause infection and diarrhea in immunocompromised individuals, such as those with HIV. In immunocompetent individuals, this organism typically does not cause symptoms. However, in those with HIV, particularly those with low CD4 counts, Cryptosporidium can lead to prolonged, severe, or extraintestinal infection.

Other potential causes of persistent watery diarrhea in patients with HIV include Salmonella infection, colorectal cancer, and side effects of HAART therapy. However, in the context of HIV and diarrhea, Cryptosporidium should be the top consideration. It is important to consider the patient’s immune status and CD4 count when evaluating the cause of persistent diarrhea in HIV patients.

Common Causes of Diarrhoea in Immunocompromised Patients

Immunocompromised patients, particularly those with HIV infection, are at increased risk of developing chronic diarrhoea. Among the causative organisms, Cryptosporidium is the most commonly isolated. This intracellular protozoan parasite can cause severe debilitating diarrhoea with weight loss and malabsorption in HIV-infected patients. Treatment involves fluid rehydration, electrolyte correction, and pain management, with the initiation of highly active antiretroviral therapy (HAART) being crucial for restoring immunity.

Salmonella, Isospora belli, Campylobacter, and Shigella are other common causes of diarrhoea in immunosuppressed patients. Salmonella infection typically occurs after eating uncooked foods such as chicken, while Isospora species can also cause diarrhoea but not as commonly as Cryptosporidium. Campylobacter infection can present with a flu-like prodrome, fever, and in severe cases, bloody diarrhoea and severe colitis. Treatment often involves quinolones, but one complication to be wary of is the subsequent development of neurological symptoms due to Guillain–Barré syndrome. Shigella infection typically presents with bloody diarrhoea after ingestion of the toxin.

HIV-positive patients are at an increased risk for opportunistic infections (OIs) due to their compromised immune system. When a low hemoglobin level is present in these patients, it may indicate an underlying OI that is causing anemia. Anemia can be a common complication of OIs such as mycobacterium avium complex (MAC), cytomegalovirus (CMV), or disseminated histoplasmosis.

Prompt diagnosis and treatment of the underlying OI is crucial in these cases to prevent further complications and improve the patient’s overall health.

In contrast, conditions such as hyperlipidemia, immune reconstitution inflammatory syndrome (IRIS), osteoporosis, and lipomastia may also be present in HIV-positive patients, but they do not typically present with a low hemoglobin level as a primary symptom. Therefore, when a low hemoglobin level is identified in an HIV-positive patient, the focus should be on ruling out and treating any underlying opportunistic infections.